Skip to main content
Erschienen in:

30.10.2019 | Special Edition

Surgery and stereotactic body radiotherapy for early-stage non-small cell lung cancer: prospective clinical trials of the past, the present, and the future

verfasst von: Masatsugu Hamaji

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Stereotactic body radiotherapy (SBRT) may be a potential alternative to surgical resection in high-risk operable patients with early-stage non-small cell lung cancer (NSCLC). A number of clinical studies have been undertaken to answer this question, although the conclusion has remained undetermined. Although three randomized clinical trials have failed, currently several prospective clinical trials are ongoing on SBRT versus surgery for early-stage NSCLC. This review article was designed to overview the previous and ongoing clinical trials and to discuss the future perspectives in the comparisons.
Literatur
1.
Zurück zum Zitat Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352–8.CrossRef Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352–8.CrossRef
5.
Zurück zum Zitat Matsuo Y, Chen F, Hamaji M, Kawaguchi A, Ueki N, Nagata Y, et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysis. Eur J Cancer. 2014;50:2932–8.CrossRef Matsuo Y, Chen F, Hamaji M, Kawaguchi A, Ueki N, Nagata Y, et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysis. Eur J Cancer. 2014;50:2932–8.CrossRef
6.
Zurück zum Zitat Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013;24:1543–8.CrossRef Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013;24:1543–8.CrossRef
7.
Zurück zum Zitat Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy 411 or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28:928–35.CrossRef Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy 411 or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28:928–35.CrossRef
8.
Zurück zum Zitat Nakagawa T, Negoro Y, Matsuoka T, Okumura N, Dodo Y. Comparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancer. Respir Investig. 2014;52:221–6.CrossRef Nakagawa T, Negoro Y, Matsuoka T, Okumura N, Dodo Y. Comparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancer. Respir Investig. 2014;52:221–6.CrossRef
9.
Zurück zum Zitat Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ. 2016;8(354):i3570.CrossRef Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ. 2016;8(354):i3570.CrossRef
10.
Zurück zum Zitat Hamaji M, Chen F, Matsuo Y, Kawaguchi A, Morita S, Ueki N, Sonobe M, Nagata Y, Hiraoka M, Date H. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg. 2015;99:1122–9.CrossRef Hamaji M, Chen F, Matsuo Y, Kawaguchi A, Morita S, Ueki N, Sonobe M, Nagata Y, Hiraoka M, Date H. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg. 2015;99:1122–9.CrossRef
11.
Zurück zum Zitat Port JL, Parashar B, Osakwe N, Nasar A, Lee PC, Paul S, et al. A propensity-matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer. Ann Thorac Surg. 2014;98:1152–9.CrossRef Port JL, Parashar B, Osakwe N, Nasar A, Lee PC, Paul S, et al. A propensity-matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer. Ann Thorac Surg. 2014;98:1152–9.CrossRef
12.
Zurück zum Zitat Wang HH, Zhang CZ, Zhang BL, Chen J, Zeng XL, Deng L, et al. Sublobar resection is associated with improved outcomes over radiotherapy in the management of high-risk elderly patients with Stage I non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:6033–42.CrossRef Wang HH, Zhang CZ, Zhang BL, Chen J, Zeng XL, Deng L, et al. Sublobar resection is associated with improved outcomes over radiotherapy in the management of high-risk elderly patients with Stage I non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:6033–42.CrossRef
13.
Zurück zum Zitat Ma L, Xiang J. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: a meta-analysis. Thorac Cancer. 2016;7:442–51.CrossRef Ma L, Xiang J. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: a meta-analysis. Thorac Cancer. 2016;7:442–51.CrossRef
14.
Zurück zum Zitat Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014;90:603–11.CrossRef Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014;90:603–11.CrossRef
15.
Zurück zum Zitat Zhang B, Zhu F, Ma X, Tian Y, Cao D, Luo S, Xuan Y, Liu L, Wei Y. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;112:250–5.CrossRef Zhang B, Zhu F, Ma X, Tian Y, Cao D, Luo S, Xuan Y, Liu L, Wei Y. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;112:250–5.CrossRef
16.
Zurück zum Zitat Li M, Yang X, Chen Y, Yang X, Dai X, Sun F, et al. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:2885–922.CrossRef Li M, Yang X, Chen Y, Yang X, Dai X, Sun F, et al. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:2885–922.CrossRef
17.
Zurück zum Zitat Chen H, Laba JM, Boldt RG, Goodman CD, Palma DA, Senan S, et al. Stereotactic ablative radiation therapy versus surgery in early lung cancer: a meta-analysis of propensity score studies. Int J Radiat Oncol Biol Phys. 2018;101:186–94.CrossRef Chen H, Laba JM, Boldt RG, Goodman CD, Palma DA, Senan S, et al. Stereotactic ablative radiation therapy versus surgery in early lung cancer: a meta-analysis of propensity score studies. Int J Radiat Oncol Biol Phys. 2018;101:186–94.CrossRef
18.
Zurück zum Zitat Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–7.CrossRef Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–7.CrossRef
19.
Zurück zum Zitat Treasure T, Rintoul RC, Macbeth F. SABR in early operable lung cancer: time for evidence. Lancet Oncol. 2015;16:597–8.CrossRef Treasure T, Rintoul RC, Macbeth F. SABR in early operable lung cancer: time for evidence. Lancet Oncol. 2015;16:597–8.CrossRef
20.
Zurück zum Zitat Hamaji M, Groth SS, Sugarbaker DJ, Burt BM. Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncol. 2015;16:e372.CrossRef Hamaji M, Groth SS, Sugarbaker DJ, Burt BM. Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncol. 2015;16:e372.CrossRef
21.
Zurück zum Zitat Dearman C, van As N, Crellin A, Slevin N, Sharma RA. Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncol. 2015;16:e373–e374374.CrossRef Dearman C, van As N, Crellin A, Slevin N, Sharma RA. Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncol. 2015;16:e373–e374374.CrossRef
22.
Zurück zum Zitat Opitz I, Rocco G, Brunelli A, Varela G, Massard G, Weder W, European Society of Thoracic Surgeons. Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncol. 2015;16:e372–e373373.CrossRef Opitz I, Rocco G, Brunelli A, Varela G, Massard G, Weder W, European Society of Thoracic Surgeons. Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncol. 2015;16:e372–e373373.CrossRef
23.
Zurück zum Zitat Zhang L, Tian J, Wang C. Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncol. 2015;16:e371–e372372.CrossRef Zhang L, Tian J, Wang C. Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncol. 2015;16:e371–e372372.CrossRef
24.
Zurück zum Zitat Meyers BF, Puri V, Broderick SR, Samson P, Keogan K, Crabtree TD. Lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer: post hoc analysis dressed up as level-1 evidence? J. Thorac. Cardiovasc. Surg. 2015;150:468–71.CrossRef Meyers BF, Puri V, Broderick SR, Samson P, Keogan K, Crabtree TD. Lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer: post hoc analysis dressed up as level-1 evidence? J. Thorac. Cardiovasc. Surg. 2015;150:468–71.CrossRef
25.
Zurück zum Zitat Jones DR. Do we know bad science when we see it? J Thorac Cardiovasc Surg. 2015;150:472–3.CrossRef Jones DR. Do we know bad science when we see it? J Thorac Cardiovasc Surg. 2015;150:472–3.CrossRef
26.
Zurück zum Zitat Cassivi SD, Allen MS, Vanderwaerdt GD, Ewoldt LL, Cordes ME, Wigle DA, Nichols FC, Pairolero PC, Deschamps C. Patient-centered quality indicators for pulmonary resection. Ann Thorac Surg. 2008;86:927–32.CrossRef Cassivi SD, Allen MS, Vanderwaerdt GD, Ewoldt LL, Cordes ME, Wigle DA, Nichols FC, Pairolero PC, Deschamps C. Patient-centered quality indicators for pulmonary resection. Ann Thorac Surg. 2008;86:927–32.CrossRef
Metadaten
Titel
Surgery and stereotactic body radiotherapy for early-stage non-small cell lung cancer: prospective clinical trials of the past, the present, and the future
verfasst von
Masatsugu Hamaji
Publikationsdatum
30.10.2019
Verlag
Springer Singapore
Erschienen in
General Thoracic and Cardiovascular Surgery / Ausgabe 7/2020
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-019-01239-8

Neu im Fachgebiet Chirurgie

Krebs-Op. besser erst nach mehrwöchigem Rauchverzicht?

Aktive Raucher haben nach onkologischen Operationen ein höheres Komplikationsrisiko als Nieraucher, aber auch als Exraucher. Damit der Rauchstopp einen Nutzen hat, darf er aber nicht zu kurz vor der Op. erfolgen, wie eine Metaanalyse nahelegt.

Periprozeduraler Myokardschaden nach NSTEMI prognostisch bedeutsam

Erleiden NSTEMI-Patienten und -Patientinnen infolge einer PCI Myokardschädigungen mit oder ohne Infarkt, erhöht das die Gesamtmortalität und das Risiko für weitere schwere Herzereignisse. Dafür sprechen zumindest Daten aus zwei italienischen Zentren.

Höhere Sterberate nach Freitags-Op.

Wer direkt vor dem Wochenende operiert wird, läuft eher Gefahr, in den folgenden Wochen und Monaten zu sterben, als Menschen mit einer Op. unmittelbar nach dem Wochenende. Der Unterschied bei der Sterberate beläuft sich nach Daten einer US-Analyse auf etwa 10%.

Ärztinnen überholen Ärzte bei Praxisgründungen

Bei Praxisgründungen haben inzwischen die Frauen deutlich die Nase vorn: Seit zehn Jahren wagen laut apoBank mehr Ärztinnen als Ärzte den Schritt in die Selbstständigkeit. In puncto Finanzierung sind sie aber vorsichtiger als die männlichen Kollegen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.